Teva Highlights Long-Term AUSTEDO Success in Tardive Dyskinesia Care
PARSIPPANY, N.J. and TEL AVIV, Israel, June 20, 2026 Teva Pharmaceutical Industries Ltd. has unveiled compelling new long-term data...
AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
PARSIPPANY, N.J. and TEL AVIV, Israel, June 20, 2026 Teva Pharmaceutical Industries Ltd. has unveiled compelling new long-term data...
BOSTON, MA, June 18, 2026 Curiumâ„¢ has secured a significant legal and commercial milestone after prevailing in a patent...
CAMBRIDGE, Massachusetts, ROTTERDAM, Netherlands, and SHANGHAI, China, June 14, 2026 Harbour BioMed has secured a major legal victory in...
